-
1.发明申请Recombinant Antibodies to the Vascular Endothelial Growth Factor (VEGF) which are Obtained by Means of Mutagenesis of Variable Regions 有权通过变异区域诱变获得的血管内皮生长因子（VEGF）的重组抗体公开(公告)号：US20140086829A1
公开(公告)日：2014-03-27
申请号：US13976060
申请日：2011-12-26
申请人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Munoz Pozo , Amaury Pupo Merino , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
发明人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Munoz Pozo , Amaury Pupo Merino , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
CPC分类号： C07K16/22 , A61K51/1021 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others.
摘要翻译： 本发明揭示识别人血管内皮生长因子A（VEGF-A）的人重组抗体，阻断其与VEGFR2受体的相互作用，并且干扰其在体内的增殖作用和促血管生成作用。 抗体鉴定了与之前报道的任何其它VEGF不同的人VEGF-A上的表位，并且通过将一个免疫球蛋白轻链可变区与其他三个重链可变区组合获得。 通过人免疫球蛋白可变区诱变获得抗体，并且可用于与脉管系统增加相关的病理实体的免疫治疗，例如年龄相关性黄斑变性，癌症等。
-
公开(公告)号：US20100047265A1
公开(公告)日：2010-02-25
申请号：US12612455
申请日：2009-11-04
申请人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vásquez Blomquist
发明人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vásquez Blomquist
IPC分类号： A61K39/00 , A61K31/7088 , A61P35/00 , A61P35/04
CPC分类号： C07K14/715 , A61K38/1858 , A61K38/1866 , A61K39/0005 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K48/005 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55516 , A61K2039/55594 , C07K14/515 , C07K14/52 , C07K14/71
摘要： Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
摘要翻译： 血管通透性因子（VPF）家族的分子的寡核苷酸和多肽序列在病理实体的主动免疫治疗中的应用及其修饰，其中该过程与增加相关 血管生成。 这些方法可以用于治疗癌症及其转移，急性和慢性炎症过程，感染性疾病，自身免疫性疾病，糖尿病和新生儿视网膜病变，器官移植排斥，黄斑变性，新生血管性青光眼，血管瘤和 血管纤维瘤等。
-
3.发明授权公开(公告)号：US09505830B2
公开(公告)日：2016-11-29
申请号：US13976060
申请日：2011-12-26
申请人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Muñoz Pozo , Amaury Pupo Meriño , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
发明人： Humberto Lamdan Ordas , Jorge Victor Gavilondo Cowley , Marta Ayala Avila , Yasmiana Muñoz Pozo , Amaury Pupo Meriño , Gertrudis Rojas Dorantes , Lincidio Perez Sanchez
IPC分类号： C07K16/22 , A61K39/395 , A61K51/10 , A61K39/00
CPC分类号： C07K16/22 , A61K51/1021 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with an increase in vasculature, such as age-related macular degeneration, cancer, and others.
摘要翻译： 本发明揭示识别人血管内皮生长因子A（VEGF-A）的人重组抗体，阻断其与VEGFR2受体的相互作用，并且干扰其在体内的增殖作用和促血管生成作用。 抗体鉴定了与之前报道的任何其它VEGF不同的人VEGF-A上的表位，并且通过将一个免疫球蛋白轻链可变区与其他三个重链可变区组合获得。 通过人免疫球蛋白可变区诱变获得抗体，可用于与血管系统增加相关的病理实体的免疫治疗，如年龄相关性黄斑变性，癌症等。
-
公开(公告)号：US08883724B2
公开(公告)日：2014-11-11
申请号：US12612455
申请日：2009-11-04
申请人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vásquez Blomquist
发明人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vásquez Blomquist
IPC分类号： A61K38/18 , A61K39/395 , C07K14/475 , C07K16/00 , C07K14/515 , C07K14/52 , A61K48/00 , C07K14/71 , C07K14/715 , A61K39/00
CPC分类号： C07K14/715 , A61K38/1858 , A61K38/1866 , A61K39/0005 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K48/005 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55516 , A61K2039/55594 , C07K14/515 , C07K14/52 , C07K14/71
摘要： Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
摘要翻译： 血管通透性因子（VPF）家族的分子的寡核苷酸和多肽序列在病理实体的主动免疫治疗中的应用及其修饰，其中该过程与增加相关 血管生成。 这些方法可以用于治疗癌症及其转移，急性和慢性炎症过程，感染性疾病，自身免疫性疾病，糖尿病和新生儿视网膜病变，器官移植排斥，黄斑变性，新生血管性青光眼，血管瘤和 血管纤维瘤等。
-
5.发明授权Pharmaceutical composition containing polypeptide fragments of serralysins 有权含有serralysins多肽片段的药物组合物公开(公告)号：US08076297B2
公开(公告)日：2011-12-13
申请号：US11631880
申请日：2005-07-05
申请人： Maria del Carmen Abrahantes Pérez , Jesús Reyes González , Gloria Véliz Rios , Eduardo Martinez Diaz , Caridad Anais Gasmuri González , José Garcia Suárez , Mónica Bequet Romero , Luis Javier González López , Lila Rosa Castellanos Serra , Manuel Selman-Housein Sosa , Raúl Gómez Riera , Jorge Victor Gavilondo Cowley
发明人： Maria del Carmen Abrahantes Pérez , Jesús Reyes González , Gloria Véliz Rios , Eduardo Martinez Diaz , Caridad Anais Gasmuri González , José Garcia Suárez , Mónica Bequet Romero , Luis Javier González López , Lila Rosa Castellanos Serra , Manuel Selman-Housein Sosa , Raúl Gómez Riera , Jorge Victor Gavilondo Cowley
CPC分类号： A61K38/16
摘要： The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.
摘要翻译： 本发明涉及能够抑制不同组织起源的肿瘤细胞和活化的内皮细胞的生长的组合物。 所述组合物的组分是对应于来自分子末端的内部甲硫氨酸的对应于C-末端片段的血清素的多肽片段，其可以在它们之间并且任选地与促进组合物的抗肿瘤作用的催乳素蛋白质组合 。 组合物中的生殖细胞可以是0.1-100nM的浓度。 该组合物的抗增殖作用由凋亡机制介导。 “体内”治疗对恶性肿瘤具有抗肿瘤，抗血管生成和保护作用。
-
公开(公告)号：US20110218138A1
公开(公告)日：2011-09-08
申请号：US11631880
申请日：2005-07-05
申请人： María Del Carmen Abrahantes Pérez , Jesús Reyes González , Gloria Véliz Rios , Eduardo Martínez Díaz , Caridad Anais Gasmuri González , José Garcia Suárez , Mónica Bequet Romero , Luis Javier González López , Lisa Rosa Castellanos Serra , Manuel Selman-Housein Sosa , Raúl Gómez Riera , Jorge Victor Gavilondo Cowley
发明人： María Del Carmen Abrahantes Pérez , Jesús Reyes González , Gloria Véliz Rios , Eduardo Martínez Díaz , Caridad Anais Gasmuri González , José Garcia Suárez , Mónica Bequet Romero , Luis Javier González López , Lisa Rosa Castellanos Serra , Manuel Selman-Housein Sosa , Raúl Gómez Riera , Jorge Victor Gavilondo Cowley
CPC分类号： A61K38/16
摘要： The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.
-
7.发明申请Methods and Proteins for the Prophylactic and/or Therapeutic Treatment of Four Serotypes of Dengue Virus and Other Flaviviruses 审中-公开用于预防和/或治疗四种登革热病毒和其他黄病毒血清型的方法和蛋白质公开(公告)号：US20090312190A1
公开(公告)日：2009-12-17
申请号：US12094503
申请日：2006-11-21
申请人： Glay Chinea Santiago , Vivian Huerta Galindo , Alejandro Miguel Martin Dunn , Jorge Victor Gavilondo Cowley , Noralvis Fleitas Salazar , Osmany Guirola Cruz , Jeovanis Gil Valdés , Aída Zulueta Morales , Lisset Hermida Cruz , Marta Ayala Avila , Diamilé Gonzáles Roche , Rolando Paez Meireles , Patricia Gabriela Toledo Mayora , Mónica Sarria Núnez , Alexis Musacchio Lasa , Yuliet Mazola Reyes
发明人： Glay Chinea Santiago , Vivian Huerta Galindo , Alejandro Miguel Martin Dunn , Jorge Victor Gavilondo Cowley , Noralvis Fleitas Salazar , Osmany Guirola Cruz , Jeovanis Gil Valdés , Aída Zulueta Morales , Lisset Hermida Cruz , Marta Ayala Avila , Diamilé Gonzáles Roche , Rolando Paez Meireles , Patricia Gabriela Toledo Mayora , Mónica Sarria Núnez , Alexis Musacchio Lasa , Yuliet Mazola Reyes
IPC分类号： C40B30/02 , A61K39/00 , A61K39/12 , C12N7/00 , C12N5/00 , C40B30/04 , C40B40/10 , C07K16/00 , C07H21/04 , A61K39/02
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/55566 , C07K2319/02 , C07K2319/21 , C12N2770/24022 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.
摘要翻译： 本发明涉及制药工业的领域，并且描述了可用于开发用于预防和/或治疗感染的广谱抗病毒分子的E蛋白表面上的保守区域 由于登革热病毒血清型1-4和其他黄病毒。 本发明还涵盖用作疫苗的嵌合蛋白或针对登革热病毒和其他黄病毒的四种血清型的预防或治疗性治疗。
-
公开(公告)号：US07556809B2
公开(公告)日：2009-07-07
申请号：US10511384
申请日：2003-04-11
申请人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vázquez Blomquist
发明人： Mónica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernández Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vázquez Blomquist
IPC分类号： A61K39/095 , A61K39/39 , A61K38/18 , A61K38/04 , A61K39/395 , C07K4/12
CPC分类号： C07K14/715 , A61K38/1858 , A61K38/1866 , A61K39/0005 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K48/005 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55516 , A61K2039/55594 , C07K14/515 , C07K14/52 , C07K14/71
摘要： Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
摘要翻译： 血管通透性因子（VPF）家族的分子的寡核苷酸和多肽序列在病理实体的主动免疫治疗中的应用及其修饰，其中该过程与增加相关 血管生成。 这些方法可以用于治疗癌症及其转移，急性和慢性炎症过程，感染性疾病，自身免疫性疾病，糖尿病和新生儿视网膜病变，器官移植排斥，黄斑变性，新生血管性青光眼，血管瘤和 血管纤维瘤等。
-
公开(公告)号：US20080254050A1
公开(公告)日：2008-10-16
申请号：US11787522
申请日：2007-04-17
申请人： Monica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernandez Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vazquez Blomquist
发明人： Monica Bequet Romero , Boris Ernesto Acevedo Castro , Jorge Victor Gavilondo Cowley , Luis Enrique Fernandez Molina , Omar Lopez Ocejo , Ricardo de la Caridad Silva Rodriguez , Alexis Musachio Lasa , Ernesto Galban Rodriguez , Dania Marcia Vazquez Blomquist
CPC分类号： C07K14/715 , A61K38/1858 , A61K38/1866 , A61K39/0005 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K48/005 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55516 , A61K2039/55594 , C07K14/515 , C07K14/52 , C07K14/71
摘要： Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis.These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
摘要翻译： 血管通透性因子（VPF）家族的分子的寡核苷酸和多肽序列在病理实体的主动免疫治疗中的应用及其修饰，其中该过程与增加相关 血管生成。 这些方法可以用于治疗癌症及其转移，急性和慢性炎症过程，感染性疾病，自身免疫性疾病，糖尿病和新生儿视网膜病变，器官移植排斥，黄斑变性，新生血管性青光眼，血管瘤和 血管纤维瘤等。
-
公开(公告)号：US06891023B1
公开(公告)日：2005-05-10
申请号：US09889480
申请日：2000-11-16
申请人： Cristina Maria Mateo de Acosta Del Rio , Lourdes Tatiana Roque Navarro , Alejo Morales Morales , Rolando Pérez Rodríguez , Marta Ayala Ávila , Jorge Victor Gavilondo Cowley , Marta Dueñas Porto , Hanssel Bell García , Enrique Rengifo Calzado , Normando Iznaga Escobar , Mayra Ramos Zuzarte
发明人： Cristina Maria Mateo de Acosta Del Rio , Lourdes Tatiana Roque Navarro , Alejo Morales Morales , Rolando Pérez Rodríguez , Marta Ayala Ávila , Jorge Victor Gavilondo Cowley , Marta Dueñas Porto , Hanssel Bell García , Enrique Rengifo Calzado , Normando Iznaga Escobar , Mayra Ramos Zuzarte
IPC分类号： C12P21/08 , A61K39/395 , A61K51/00 , C07K16/30 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , G01N33/574 , C07K16/00
CPC分类号： C07K16/3046 , A61K2039/505 , C07K2317/24 , C07K2317/622 , G01N33/57446 , G01N2800/52
摘要： Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
摘要翻译： 由沉积有ECCC 97061101的杂交瘤产生的来自鼠抗体IOR C5的新型重组抗体。使用重组DNA技术获得重组抗体，其特征在于它们识别抗原i-C2。 重组抗体是特异性嵌合抗体，人源化抗体和单链Fv片段。 嵌合抗体含有鼠免疫球蛋白的可变结构域和人免疫球蛋白的恒定区。 人源化抗体含有人类免疫球蛋白的恒定区，并且在可能导致细胞T的抗原位点的那些区域中，在鼠框架区（FR）和后者中特异性修饰.Fv片段含有可变结构域 鼠免疫球蛋白 本发明还涉及来自鼠抗体i或C5的重组抗体在结肠直肠肿瘤的诊断和治疗中的应用，其转移和复发。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
